Ionis Pharmaceuticals director sells 5,000 shares

Ionis Pharmaceuticals director Lynne B. Parshall reported selling 5,000 shares of common stock on August 6, 2025, in open-market transactions at weighted average prices of $41.8685 and $42.6275 per share under a Rule 10b5-1 trading plan adopted May 6, 2025.

Rhea-AI Filing Summary

Ionis Pharmaceuticals director Lynne B. Parshall reported selling 5,000 shares of common stock on August 6, 2025, in open-market transactions at weighted average prices of $41.8685 and $42.6275 per share under a Rule 10b5-1 trading plan adopted May 6, 2025. After these sales, she holds 86,344 shares directly.

Insights

Corporate Governance Expert

TL;DR: Director sales under a 10b5-1 plan are routine and signal pre-planned disposition, not necessarily a change in company outlook.

The Form 4 documents two sales by Director B. Lynne Parshall totaling 5,000 shares executed on 08/06/2025 under a Rule 10b5-1 trading plan adopted May 6, 2025. This structure typically provides an affirmative defense against insider trading claims and indicates transactions were pre-authorized. The filing also includes weighted-average prices and price ranges, and offers to provide transaction-level breakdowns on request, which supports transparency in disclosure practices. Impact on investors is limited absent additional context on relative stake size or company developments.

Securities Analyst

TL;DR: The sales are a disclosed insider disposition with clear pricing; unlikely to be materially market-moving on their own.

The Form 4 shows routine sales of 4,600 and 400 shares at weighted-average prices of $41.8685 and $42.6275, with specified price ranges. The reporting person remains a director after the transactions, and the filing includes explicit post-transaction beneficial ownership figures. Because the transactions were conducted pursuant to a documented 10b5-1 plan and the filing provides price-range transparency, these disclosures reduce uncertainty but do not by themselves convey a material operational or financial change for Ionis Pharmaceuticals.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 2 txns

Insider PARSHALL B LYNNE

Role Director

Sold 5,000 shs ($210K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,600	$41.8685	$193K
Sale	Common Stock	400	$42.6275	$17K

Holdings After Transaction: Common Stock — 86,344 shares (Direct)

Footnotes (3)

1. F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.5 to $42.36 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.56 to $42.83 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Key Figures

Shares sold: 5,000 shares Sale price for 4,600 shares: $41.8685 per share Sale price for 400 shares: $42.6275 per share +2 more

5 metrics

Shares sold 5,000 shares Total common shares sold on August 6, 2025

Sale price for 4,600 shares $41.8685 per share Weighted average price reported for larger sale block

Sale price for 400 shares $42.6275 per share Weighted average price reported for smaller sale block

Post-transaction holdings 86,344 shares Common stock held directly by Lynne B. Parshall after sales

10b5-1 plan adoption date May 6, 2025 Date the Rule 10b5-1 Trading Plan was adopted

Key Terms

Rule 10b5-1 Trading Plan, weighted average price, Common Stock

3 terms

Rule 10b5-1 Trading Plan regulatory

"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Stock financial

"security_title Common Stock for the reported transactions"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ionis Pharmaceuticals (IONS) report in this Form 4?

Ionis Pharmaceuticals reported that director Lynne B. Parshall sold 5,000 shares of common stock on August 6, 2025. The trades were open-market sales executed under a pre-arranged Rule 10b5-1 Trading Plan and are disclosed as non-derivative transactions.

How many Ionis Pharmaceuticals (IONS) shares did Lynne B. Parshall sell?

Lynne B. Parshall sold a total of 5,000 common shares of Ionis Pharmaceuticals. The Form 4 breaks this into two transactions: 4,600 shares at one weighted average price and 400 shares at another weighted average price, all on August 6, 2025.

At what prices were the Ionis (IONS) shares sold by Lynne B. Parshall?

The reported sale prices are weighted averages of multiple trades: $41.8685 per share for one block and $42.6275 per share for the other. Footnotes note executions across ranges between $41.50 and $42.83 per share during the sale transactions.

Was Lynne B. Parshall’s Ionis (IONS) share sale made under a Rule 10b5-1 plan?

Yes. A footnote states the shares were sold pursuant to a Rule 10b5-1 Trading Plan adopted by Lynne B. Parshall on May 6, 2025. Such plans are pre-arranged trading programs that can reduce the informational significance of transaction timing.

How many Ionis Pharmaceuticals (IONS) shares does Lynne B. Parshall hold after this sale?

Following the reported transactions, Lynne B. Parshall holds 86,344 shares of Ionis Pharmaceuticals common stock directly. This post-transaction holding figure is explicitly reported as her canonical position in the filing’s holdings data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/08/2025 - 06:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARSHALL B LYNNE

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2025		S		4,600(1)	D	$41.8685(2)	86,744	D
Common Stock	08/06/2025		S		400(1)	D	$42.6275(3)	86,344	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.5 to $42.36 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.56 to $42.83 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: B. Lynne Parshall	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.